ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned | Zendy

Simonetta Viviani | Zendy; Pier Luigi Zinzani | Zendy; Alessandro Rambaldi | Zendy; Ercole Brusamolino | Zendy; Alessandro Levis | Zendy; V. Bonfante | Zendy; Umberto Vitolo | Zendy; Alessandro Pulsoni | Zendy; Anna Marina Liberati | Zendy; Giorgina Specchia | Zendy; Pinuccia Valagussa | Zendy; Andrea Rossi | Zendy; Francesco Zaja | Zendy; Enrico Maria Pogliani | Zendy; Patrizia Pregno | Zendy; Manuel Gotti | Zendy; Andrea Gallamini | Zendy; Delia Rota Scalabrini | Zendy; Gianni Bonadonna | Zendy; Alessandro M. Gianni | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

ABVD versus BEACOPP for Hodgkin's Lymphoma When High-Dose Salvage Is Planned

Author(s) -

Simonetta Viviani,

Pier Luigi Zinzani,

Alessandro Rambaldi,

Ercole Brusamolino,

Alessandro Levis,

V. Bonfante,

Umberto Vitolo,

Alessandro Pulsoni,

Anna Marina Liberati,

Giorgina Specchia,

Pinuccia Valagussa,

Andrea Rossi,

Francesco Zaja,

Enrico Maria Pogliani,

Patrizia Pregno,

Manuel Gotti,

Andrea Gallamini,

Delia Rota Scalabrini,

Gianni Bonadonna,

Alessandro M. Gianni

Publication year - 2011

Publication title -

new england journal of medicine

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 19.889

H-Index - 1030

eISSN - 1533-4406

pISSN - 0028-4793

DOI - 10.1056/nejmoa1100340

Subject(s) - abvd , medicine , procarbazine , dacarbazine , vincristine , salvage therapy , regimen , surgery , vinblastine , hodgkin's lymphoma , oncology , cyclophosphamide , chemotherapy

BEACOPP, an intensified regimen consisting of bleomycin, etoposide, doxorubicin, cyclophosphamide, vincristine, procarbazine, and prednisone, has been advocated as the new standard of treatment for advanced Hodgkin's lymphoma, in place of the combination of doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD).

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research